
Insider and congress filings
HCA Healthcare, Inc. (HCA)
NYSE · Healthcare · 337 insider transactions · 90 congress trades · last filed 2 months agoS&P 500
About HCA Healthcare, Inc.
from the company's filings and listing, as of Oct 27, 2026- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Chief executive
- Samuel N. Hazen
- Employees
- 320,000
- Listed since
- Mar 10, 2011
- Market value
- $100.7B
- Price to earnings (12 mo)
- 15.5
- Net income per share, as reported (12 mo)
- $30.70
- Dividend yield
- 0.66%
Earnings
6 reported quarters · next on Oct 27, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 24, 2026 | $7.59 | $7.56 | $20.2B | $19.8B | EPS in lineRevenue beat |
| Q1 FY2026reported Apr 24, 2026 | $7.15 | $7.12 | $19.1B | $19.1B | EPS in lineRevenue in line |
| Q4 FY2025reported Jan 27, 2026 | $8.01 | $7.46 | $19.5B | $19.7B | EPS beatRevenue in line |
| Q3 FY2025reported Oct 24, 2025 | $6.96 | $5.79 | $19.2B | $18.6B | EPS beatRevenue beat |
| Q2 FY2025reported Jul 25, 2025 | $6.84 | $6.29 | $18.6B | $18.5B | EPS beatRevenue in line |
| Q1 FY2025reported Apr 25, 2025 | $6.45 | $5.75 | $18.3B | $18.3B | EPS beatRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Mar 13, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Samuel N. HazenChief Executive Officer | $1.6M | $8.5M | $16.4M | $26.5M |
| Jon M. FosterExecutive Vice President and Chief Operating Officer | $1.0M | $1.9M | $8.0M | $11.0M |
| Michael A. MarksExecutive Vice President and Chief Financial Officer | $983K | $1.8M | $7.6M | $10.4M |
| Michael R. McAleveyExecutive Vice President - Chief Legal and Administrative Officer | $1.0M | $1.3M | $3.4M | $5.7M |
| Michael S. Cuffe, M.D.Executive Vice President and Chief Clinical Officer | $975K | $1.3M | $3.5M | $5.7M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $5.1B | 13,003,600 | -2.7% | 5.84% |
| Vanguard Capital Management LLC | $4.0B | 10,141,708 | -0.4% | 4.55% |
| Sanders Capital, LLC | $3.4B | 8,828,287 | -1.4% | 3.96% |
| State Street Corp | $2.9B | 7,469,035 | -0.9% | 3.35% |
| Wellington Management Group LLP | $1.8B | 4,707,473 | +20.5% | 2.11% |
| Geode Capital Management, LLC | $1.4B | 3,668,008 | -0.7% | 1.65% |
| First Eagle Investment Management, LLC | $1.3B | 3,295,565 | +1.3% | 1.48% |
| Vanguard Portfolio Management LLC | $1.1B | 2,712,828 | -1.6% | 1.22% |
| Morgan Stanley | $1.0B | 2,586,771 | +12.7% | 1.16% |
| Goldman Sachs Group Inc | $960.8M | 2,464,314 | +15.4% | 1.11% |
| JPMorgan Chase & Co. | $896.8M | 2,285,832 | -7.2% | 1.03% |
| Arrowstreet Capital, Limited Partnership | $861.5M | 2,209,485 | +2.0% | 0.99% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Tracked fund managers holding HCA
4 managers| Manager | Value | Shares | Share of book |
|---|---|---|---|
| Darsana Capital Partners | $428.9M | 1,100,000 | 1.9% |
| Pentwater Capital Management | $50.7M | 130,000 | 0.3% |
| Element Capital Management | $5.0M | 12,900 | 0.2% |
| Brave Warrior Advisors | $1.9M | 4,833 | n/a |
4 of the 97 fund managers we track list HCA shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
Open-market insider trades
5 filings shown · newest filing first| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Michael R. McAleveyEVP & Chief Legal & Admin Off. | Sold | 1,694 | $533.37 | $904K | Feb 18, 2026filed Feb 18, 2026 | 0d |
| Jennifer BerresSVP & Chief Human Res. Officer | Sold | 4,010 | $503.00 | $2.0M | Feb 11, 2026filed Feb 12, 2026 | 1d |
| Christopher F. WyattSVP & Controller | Sold | 4,000 | $505.00 | $2.0M | Feb 11, 2026filed Feb 12, 2026 | 1d |
| Michael S. CuffeEVP and Chief Clinical Officer | Sold | 1,500 | $498.09 | $747K | Feb 3, 2026filed Feb 5, 2026 | 2d |
| Samuel N. HazenCEO | Sold · 7 lines | 42,877 | $501.04 | $21.5M | Feb 3, 2026filed Feb 5, 2026 | 2d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Michael J. SchlosserEVP and Chief Clinical Officer | Other Form 4 entry (see filing) | 40,712 | Sep 1, 2026 |
| Michael R. McAleveyEVP & Chief Legal & Admin Off. | Other (see filing) | 7,769 | Aug 26, 2026 |
| Mike A. MarksEVP and CFO | Gift | 3,336 | May 7, 2026 |
| John ChidseyDirector | Stock award | 809 | Apr 28, 2026 |
| Nancy Ann DeparleDirector | Stock award | 509 | Apr 28, 2026 |
| Hugh F. JohnstonDirector | Stock award | 809 | Apr 28, 2026 |
| Michael W. MichelsonDirector | Stock award | 925 | Apr 28, 2026 |
| Wayne Joseph RileyDirector | Stock award | 509 | Apr 28, 2026 |
| Andrea B. SmithDirector | Stock award | 509 | Apr 28, 2026 |
| Thomas F. Frist IIIDirector | Stock award | 1,041 | Apr 28, 2026 |
| William R. FristDirector | Stock award | 809 | Apr 28, 2026 |
| Michael R. McAleveyEVP & Chief Legal & Admin Off. | Tax withholding | 3,306 | Feb 13, 2026 |
| Michael R. McAleveyEVP & Chief Legal & Admin Off. | Option exercise | 5,000 | Feb 13, 2026 |
| Jennifer BerresSVP & Chief Human Res. Officer | Tax withholding | 2,515 | Feb 10, 2026 |
| Jennifer BerresSVP & Chief Human Res. Officer | Stock award | 7,116 | Feb 10, 2026 |
| Michael S. CuffeEVP and Chief Clinical Officer | Tax withholding | 3,501 | Feb 10, 2026 |
| Michael S. CuffeEVP and Chief Clinical Officer | Stock award | 9,628 | Feb 10, 2026 |
| Jon M. FosterEVP and COO | Tax withholding | 5,888 | Feb 10, 2026 |
| Jon M. FosterEVP and COO | Stock award | 15,696 | Feb 10, 2026 |
| Samuel N. HazenCEO | Tax withholding | 21,323 | Feb 10, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Congress trades in HCA
20 disclosures of 90 on record · median 30d of the 45 allowedSince the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.
| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +26.6% since the tradeEstimated entry price $370.42, close on Mon Jul 20Current price $469.03, close on Fri Oct 23 | Jul 20, 2026 | Aug 7, 2026 | 18d |
| Jared MoskowitzDependent child | Stock | Purchase | $1,001 - $15,000 | +20.8% since the tradeEstimated entry price $388.16, close on Wed Jun 17Current price $469.03, close on Fri Oct 23 | Jun 17, 2026 | Jul 26, 2026 | 39d |
| Alan ArmstrongSelf | Stock | Purchase | $1,001 - $15,000 | -0.6% since the tradeEstimated entry price $471.85, close on Fri Mar 27Current price $469.03, close on Fri Oct 23 | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +10.9% since the saleEstimated exit price $423.00, close on Fri May 15Current price $469.03, close on Fri Oct 23 | May 15, 2026 | Jun 9, 2026 | 25d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +0.3% since the saleEstimated exit price $467.83, close on Mon Mar 30Current price $469.03, close on Fri Oct 23 | Mar 30, 2026 | Apr 7, 2026 | 8d |
| Ro Khanna | Stock | Sale | $15,001 - $50,000 | -12.3% since the saleEstimated exit price $534.78, close on Tue Feb 17Current price $469.03, close on Fri Oct 23 | Feb 17, 2026 | Mar 9, 2026 | 20d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +0.3% since the saleEstimated exit price $467.86, close on Mon Oct 27, 2025Current price $469.03, close on Fri Oct 23 | Oct 27, 2025 | Nov 6, 2025 | 10d |
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +16.4% since the saleEstimated exit price $402.85, close on Thu Sep 11, 2025Current price $469.03, close on Fri Oct 23 | Sep 11, 2025 | Oct 22, 2025 | 41d |
| Lisa C. McClainSpouse | Stock | Purchase | $1,001 - $15,000 | +16.5% since the tradeEstimated entry price $402.69, close on Tue Aug 19, 2025Current price $469.03, close on Fri Oct 23 | Aug 19, 2025 | Sep 12, 2025 | 24d |
| Val T. HoyleSpouse | Stock | Purchase | $1,001 - $15,000 | +30.0% since the tradeEstimated entry price $360.67, close on Tue Oct 29, 2024Current price $469.03, close on Fri Oct 23 | Oct 29, 2024 | Sep 12, 2025 | 318d |
| Val T. HoyleSpouse | Stock | Sale | $1,001 - $15,000 | +55.0% since the saleEstimated exit price $302.52, close on Fri Dec 27, 2024Current price $469.03, close on Fri Oct 23 | Dec 27, 2024 | Sep 12, 2025 | 259d |
| Jared MoskowitzDependent child | Stock | Purchase | $1,001 - $15,000 | +21.7% since the tradeEstimated entry price $385.50, close on Thu May 15, 2025Current price $469.03, close on Fri Oct 23 | May 15, 2025 | Jun 27, 2025 | 43d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +29.9% since the saleEstimated exit price $360.98, close on Wed May 7, 2025Current price $469.03, close on Fri Oct 23 | May 7, 2025 | Jun 10, 2025 | 34d |
| Ro Khanna | Stock | Sale | $15,001 - $50,000 | +29.9% since the saleEstimated exit price $360.98, close on Wed May 7, 2025Current price $469.03, close on Fri Oct 23 | May 7, 2025 | Jun 10, 2025 | 34d |
| Julie JohnsonJoint | Stock | Sale | $1,001 - $15,000 | +42.3% since the saleEstimated exit price $329.63, close on Mon Apr 7, 2025Current price $469.03, close on Fri Oct 23 | Apr 7, 2025 | May 14, 2025 | 37d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +49.9% since the tradeEstimated entry price $312.87, close on Wed Mar 12, 2025Current price $469.03, close on Fri Oct 23 | Mar 12, 2025 | Apr 10, 2025 | 29d |
| Robert Bresnahan | Stock | Sale | $1,001 - $15,000 | +40.8% since the saleEstimated exit price $333.07, close on Tue Feb 25, 2025Current price $469.03, close on Fri Oct 23 | Feb 25, 2025 | Mar 27, 2025 | 30d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +40.8% since the tradeEstimated entry price $333.07, close on Tue Feb 25, 2025Current price $469.03, close on Fri Oct 23 | Feb 25, 2025 | Mar 6, 2025 | 9d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +51.1% since the tradeEstimated entry price $310.45, close on Fri Jan 17, 2025Current price $469.03, close on Fri Oct 23 | Jan 17, 2025 | Feb 6, 2025 | 20d |
| Ro Khanna | Stock | Sale | $1,001 - $15,000 | +46.8% since the saleEstimated exit price $319.51, close on Wed Jan 22, 2025Current price $469.03, close on Fri Oct 23 | Jan 22, 2025 | Feb 6, 2025 | 15d |
Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it. On an option line the prices are the stock's, never the option's: the premium is never disclosed.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no prices or move are shown for that row.
Every Congress trade in HCA, filterable by party, chamber, type and account.
Members of Congress reporting a position
6 members · estimate, as of Oct 21, 20266 members report a position (estimated). The largest estimated position is in the $15,001 - $50,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Jared Moskowitz | Democrat · House | $15,001 - $50,000 | 0.7% |
| Gilbert Ray Cisneros, Jr. | Democrat · House | $15,001 - $50,000 | 0.1% |
| Jimmy Patronis | Republican · House | $15,001 - $50,000 | 1.7% |
| Lucy McBath | Democrat · House | $15,001 - $50,000 | 0.3% |
| Robert Bresnahan | Republican · House | $15,001 - $50,000 | 0.1% |
| Cliff Bentz | Republican · House | $1,001 - $15,000 | 0.5% |
Estimate, as of Oct 21, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, marked to the latest close we hold. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Are insiders buying or selling HCA?
Across the 5 most recent open-market filings shown here, 0 were purchases and 5 were sales.
Which members of Congress have traded HCA?
Ro Khanna, Jared Moskowitz, Alan Armstrong, Lisa C. McClain, Val T. Hoyle, Julie Johnson and others disclosed HCA transactions in the filings shown here.
Which members of Congress hold HCA?
6 members of Congress report a position in HCA in the estimate we hold as of Oct 21, 2026. The largest estimated positions, in the $15,001 - $50,000 band, include Jared Moskowitz, Gilbert Ray Cisneros, Jr. and Jimmy Patronis. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is HCA in the S&P 500 or the Nasdaq 100?
HCA Healthcare, Inc. is a current member of the S&P 500, per the membership list we hold as of Oct 27, 2026. Current members of either index get a page here whatever their filing history.
How quickly are HCA trades disclosed?
Insider filings on this page reached the public a median of 1 business day after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 30 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 27, 2026.
